Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Continuation Study of TRC105 Therapy for Patients Who Have Completed a Prior TRC105 Trial and Are Judged by the Investigator to Have the Potential to Benefit From Continued TRC105 Therapy

Next Previous
Trial Profile

An Open Label Continuation Study of TRC105 Therapy for Patients Who Have Completed a Prior TRC105 Trial and Are Judged by the Investigator to Have the Potential to Benefit From Continued TRC105 Therapy

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 16 Feb 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carotuximab (Primary) ; Axitinib; Bevacizumab; Capecitabine; Pazopanib
  • Indications Solid tumours
  • Focus Expanded access; Therapeutic Use
  • Sponsors TRACON Pharmaceuticals

Most Recent Events

  • 12 Apr 2019 According to a TRACON Pharmaceuticals media release, based on a review of TAPPAS trial data, the Independent Data Monitoring Committee (IDMC) recommended to terminate TAPPAS trial. The company also decided to terminate further enrollment in company sponsored trials of TRC105 in oncology.
  • 12 Apr 2019 Status changed from recruiting to discontinued.
  • 05 Feb 2015 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top